Meridian Bioscience (VIVO) Releases Earnings Results, Misses Expectations By $-0.01 EPS

Meridian Bioscience (VIVO) reported quarterly earnings results on Thursday, Jul-28-2016. The company reported $0.21 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $0.22. The company posted revenue of $50.70 million in the period, compared to analysts expectations of $52.87 million. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.

Meridian Bioscience closed down -0.48 points or -2.34% at $20 with 3,38,039 shares getting traded on Thursday. Post opening the session at $20.31, the shares hit an intraday low of $19.82 and an intraday high of $20.5 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

In a different news, on May 2, 2016, Catherine Sazdanoff (director) purchased 7,700 shares at $19.20 per share price. According to the SEC, on Dec 10, 2015, Vecheslav A Elagin (EVP, Research & Development) sold 7,500 shares at $19.75 per share price. On Dec 2, 2015, Richard Eberly (EVP,Pres Meridian Life Science) sold 4,934 shares at $19.61 per share price, according to the Form-4 filing with the securities and exchange commission.

Meridian Bioscience Inc. (Meridian) is an integrated life science company. The Company is engaged in developing manufacturing selling and distribution of clinical diagnostic test kits for certain gastrointestinal viral respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens antibodies polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents nucleotides competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.

Meridian Bioscience

Leave a Reply

Meridian Bioscience - Is it time to Sell?

Top Brokerage Firms are advising their investors on Meridian Bioscience. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.